Last 47 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Haemonetics Corporation's quarterly P/E stands at 21.1x, down 19.4% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 12.9% YoY to 11.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.90 | 21.13 | 14.87 | 26.36 | 13.58 | 26.21 | 30.23 | 27.95 | 53.34 | 35.05 | 46.66 | 26.61 | 36.29 |
| — | -19.4% | -50.8% | -5.7% | -74.5% | -25.2% | -35.2% | +5.0% | +47.0% | +14.1% | +61.3% | -39.9% | -56.4% | |
| P/S Ratio | 1.80 | 2.78 | 1.75 | 2.78 | 2.38 | 2.82 | 2.96 | 3.17 | 3.20 | 3.27 | 3.62 | 3.51 | 3.48 |
| — | -1.3% | -40.7% | -12.5% | -25.6% | -13.9% | -18.2% | -9.6% | -8.2% | -0.8% | +12.8% | +5.5% | +13.6% | |
| P/B Ratio | 3.25 | 4.14 | 2.70 | 4.04 | 3.83 | 4.33 | 4.65 | 4.71 | 4.57 | 4.66 | 5.15 | 5.06 | 5.18 |
| — | -4.5% | -41.9% | -14.2% | -16.2% | -7.1% | -9.7% | -6.8% | -11.8% | -10.2% | -1.6% | +11.9% | +19.6% | |
| P/FCF | 17.17 | 10.81 | 5.40 | 65.40 | 7.79 | 27.88 | 25.95 | — | 20.17 | — | 15.46 | 115.97 | 15.65 |
| — | -61.2% | -79.2% | — | -61.4% | — | +67.9% | — | +28.8% | — | -17.3% | — | -36.5% | |
| EV / EBITDA | 10.17 | 11.95 | 9.29 | 13.62 | 10.20 | 13.72 | 15.49 | 18.67 | 25.60 | 18.26 | 21.45 | 15.84 | 23.32 |
| — | -12.9% | -40.0% | -27.1% | -60.2% | -24.8% | -27.8% | +17.9% | +9.8% | +6.8% | +37.7% | -17.0% | +2.0% | |
| EV / EBIT | 15.17 | 17.01 | 13.78 | 17.33 | 14.24 | 18.27 | 20.98 | 25.23 | 25.39 | 21.51 | 29.42 | 22.60 | 25.51 |
| — | -6.9% | -34.3% | -31.3% | -43.9% | -15.1% | -28.7% | +11.6% | -0.5% | -18.5% | +26.1% | -31.1% | -8.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Haemonetics Corporation's operating margin was 20.5% in Q3 2026, up 2.7 pp QoQ and up 3.6 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 19.2% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.2% | 56.5% | 59.5% | 59.7% | 58.4% | 57.4% | 55.3% | 53.3% | 55.0% | 55.0% | 53.6% | 53.8% | 54.0% |
| — | -1.6% | +7.5% | +11.9% | +6.1% | +4.3% | +3.2% | -0.9% | +2.0% | +5.8% | +1.0% | -1.0% | -7.2% | |
| Operating Margin | 16.3% | 20.5% | 17.9% | 16.8% | 21.6% | 16.9% | 15.0% | 11.8% | 8.7% | 13.7% | 11.1% | 17.2% | 11.6% |
| — | +21.2% | +19.4% | +41.7% | +147.4% | +23.9% | +34.9% | -31.4% | -24.7% | -3.5% | -29.4% | +46.5% | +59.9% | |
| Net Margin | 12.3% | 13.2% | 11.8% | 10.6% | 17.5% | 10.8% | 9.8% | 11.4% | 5.9% | 9.3% | 7.8% | 13.2% | 9.7% |
| — | +22.7% | +20.7% | -7.2% | +195.6% | +15.8% | +25.1% | -13.4% | -38.5% | -13.9% | -29.8% | +73.4% | +162.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.8% | 5.1% | 4.5% | 4.0% | 6.7% | 4.2% | 3.8% | 4.1% | 2.1% | 3.4% | 2.8% | 4.9% | 3.7% |
| — | +21.0% | +17.8% | -2.9% | +213.6% | +23.5% | +33.8% | -15.7% | -41.9% | -22.3% | -36.0% | +86.5% | +180.1% | |
| ROA | 7.2% | 1.8% | 1.6% | 1.4% | 2.3% | 1.5% | 1.3% | 1.6% | 0.9% | 1.5% | 1.3% | 2.1% | 1.5% |
| — | +22.3% | +18.1% | -14.5% | +151.2% | -0.0% | +6.5% | -23.1% | -39.9% | -15.7% | -30.4% | +95.0% | +192.0% | |
| ROIC | 10.0% | 2.9% | 2.4% | 2.3% | 3.0% | 2.4% | 2.2% | 1.8% | 1.4% | 2.4% | 2.0% | 3.0% | 2.0% |
| — | +20.0% | +13.1% | +28.7% | +115.4% | +3.9% | +8.1% | -41.9% | -30.7% | -4.7% | -25.0% | +71.3% | +78.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Haemonetics Corporation's Debt/EBITDA ratio is 12.6x, down from 14.1x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 56.0% YoY to 1.75x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.49 | 1.34 | 1.44 | 1.39 | 1.49 | 1.35 | 1.39 | 1.35 | 0.84 | 0.92 | 0.85 | 0.88 | 0.94 |
| — | -0.5% | +3.5% | +2.7% | +77.3% | +46.3% | +63.4% | +52.8% | -10.1% | -6.6% | -24.0% | -11.5% | -10.1% | |
| Debt / EBITDA | 3.70 | 12.63 | 14.12 | 14.82 | 12.30 | 13.91 | 15.14 | 17.76 | 16.49 | 12.52 | 13.04 | 9.99 | 15.13 |
| — | -9.2% | -6.7% | -16.5% | -25.4% | +11.1% | +16.1% | +77.7% | +9.0% | +9.2% | +12.4% | -31.4% | -20.1% | |
| Current Ratio | 1.62 | 1.75 | 1.64 | 1.72 | 1.62 | 3.97 | 3.49 | 3.76 | 2.56 | 2.92 | 3.28 | 3.38 | 3.06 |
| — | -56.0% | -53.0% | -54.3% | -36.8% | +35.9% | +6.5% | +11.2% | -16.3% | -6.1% | +20.0% | -11.2% | +78.8% | |
| Quick Ratio | 0.99 | 1.15 | 1.03 | 1.04 | 0.99 | 2.55 | 2.09 | 2.33 | 1.50 | 1.76 | 2.19 | 2.16 | 2.03 |
| — | -54.8% | -50.9% | -55.3% | -34.5% | +44.9% | -4.6% | +7.5% | -25.8% | -11.3% | +24.8% | -4.8% | +93.6% | |
| Interest Coverage | 25.35 | 8.38 | 8.11 | 15.94 | 119.29 | 7.26 | 8.55 | — | 7.57 | 30.27 | 17.25 | 25.93 | 17.59 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying HAE stock.
Haemonetics Corporation's current P/E is 15.9x. The average P/E over the last 4 quarters is 19.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Haemonetics Corporation's current operating margin is 16.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Haemonetics Corporation's business trajectory between earnings reports.